circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT

    Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT
  • Webcast
    X 21st Annual H. C. Wainwright Global Investment Conference
    Sep 10, 2019 1:20 PM EDT

    21st Annual H. C. Wainwright Global Investment Conference
    Sep 10, 2019 1:20 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
Faster Progressing Patients Who Received Reldesemtiv in the Trial Demonstrated Statistically Significant Differences in the Decline in ALSFRS-R Total Score   SOUTH SAN FRANCISCO, Calif. , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses
Toggle Summary Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald Global Healthcare Conference on Thursday,
Toggle Summary Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS ( F unctional  O utcomes in a  R andomized  T rial of  I nvestigational  T reatment with CK-2127107 to  U nderstand  D ecline in  E
Toggle Summary Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15 th , 2019 SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a

EVENTS

There are currently no events to display.